Multi-omics characterization reveals the pathogenesis of liver focal nodular hyperplasia

• Published in: iScience 2022-09, Vol.25 (9), p.104921-104921, Article 104921
• Main Authors: Liu, Yuming, Zhang, Jinmai, Wang, Zhuo, Ma, Jiaqiang, Wang, Ke, Rao, Dongning, Zhang, Mao, Lin, Youpei, Wu, Yingcheng, Yang, Zijian, Dong, Liangqing, Ding, Zhenbin, Zhang, Xiaoming, Fan, Jia, Shi, Yongyong, Gao, Qiang
• Format: Article
• Language: English
• Subjects: Genetics; Hepatology; Molecular biology; Omics; Transcriptomics
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2022.104921

The molecular landscape and pathogenesis of focal nodular hyperplasia (FNH) have yet to be elucidated. We performed multi-omics approaches on FNH and paired normal liver tissues from 22 patients, followed by multi-level bioinformatic analyses and experimental validations. Generally, FNH had low mutation burden with low variant allele frequencies, and the mutation frequency significantly correlated with proliferation rate. Although no recurrently deleterious genomic events were found, some putative tumor suppressors or oncogenes were involved. Mutational signatures indicated potential impaired mismatch function and possible poison contact. Integrated analyses unveiled a group of FNH specific endothelial cells that uniquely expressed SOST and probably had strong interaction with fibroblasts through PDGFB/PDGFRB pathway to promote fibrosis. Notably, in one atypical FNH (patient No.11) with pronounced copy number variations, we observed a unique immune module. Most FNH are benign, but molecularly atypical FNH still exist; endothelial cell derived PDGFB probably promotes the fibrogenic process in FNH. [Display omitted] •FNHs are genetically stable, but high mutation cases exist•FNHs have unique transcriptomic modules, and they alter in atypical FNH•FNH has a unique type of SOST-expressing endothelial cells that may promote fibrosis